Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib

Published:2020-01 Issue:1 Volume:31 Page:153-159
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ascierto P.A.,Lewis K.D.,Di Giacomo A.M.,Demidov L.,Mandalà M.,Bondarenko I.,Herbert C.,Mackiewicz A.,Rutkowski P.,Guminski A.,Simmons B.,Ye C.,Hooper G.,Wongchenko M.J.,Goodman G.R.,Yan Y.,Schadendorf D.

Funder

F. Hoffman-La Roche Ltd

Roche

Genentech

AMD

Bristol-Myers Squibb

Pierre Fabre

GlaxoSmithKline

Merck Sharp & Dohme

Novartis

Merck KGaA

Sun Pharma

Pfizer

Sanofi

Regeneron

Amgen

Boehringer Ingelheim

Leo Pharma

AstraZeneca

Array

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference23 articles.

1. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

2. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

3. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

4. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

5. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells;Biomedicine & Pharmacotherapy;2023-12

2. Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-11-07

3. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases;eBioMedicine;2023-07

4. Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy;Journal of Immunotherapy;2023-05-24

5. Comprehensive analysis of LILR family genes expression and tumour‐infiltrating immune cells in early‐stage pancreatic ductal adenocarcinoma;IET Systems Biology;2023-02-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3